G

Gilead Sciences

Makes medicines for HIV, liver disease and cancer

Director, Marketing Sciences - GDSI Oncology Integrated Insights

Product MarketingConfirmed live in the last 24 hours
Full-timeFoster City, CA, USAHybrid

About the Job

Requirements

  • Demonstrated hands-on expertise across strategic forecasting, commercial analytics, and qualitative and quantitative market research in biopharmaceuticals or healthcare.
  • Ability to independently understand, audit, modify, and build patient-based and revenue forecast models in Excel; experience with enterprise forecasting platforms is strongly preferred.
  • Depth in oncology market dynamics, clinical evidence interpretation, treatment sequencing, launch planning, and lifecycle strategy.
  • Ability to synthesize varied and imperfect evidence, identify material assumptions, test alternative explanations, and make clear recommendations under uncertainty.
  • Experience with pharmaceutical data sources such as IQVIA/IMS, epidemiology, claims or patient-level data, treatment-pattern studies, and chart audits.
  • Ability to influence without authority, resolve disagreement, and create alignment among commercial, clinical, medical, finance, market access, corporate development, and affiliate stakeholders.
  • Ability to explain technical model logic and uncertainty in concise, decision-relevant language.
  • Strong project and vendor management, including prioritization across tight timelines and changing business needs.
  • Advanced proficiency in Microsoft Excel and PowerPoint.
  • Bachelor's degree and 12 years of relevant experience, or Master's degree and 10 years of relevant experience, or PhD and 8 years of relevant experience.

Responsibilities

  • Act as the objective insights partner to Global Strategic Marketing and cross-functional teams supporting GYN, SCLC, and selected pipeline assets.
  • Frame ambiguous business questions as decisions, hypotheses, evidence needs, and analytical workplans, with clear ownership, timing, and decision criteria.
  • Integrate forecasting, analytics, market research, competitive intelligence, epidemiology, clinical evidence, and affiliate perspectives into a coherent market view and implications for Gilead.
  • Lead discussion of findings and recommendations with senior stakeholders, distinguish evidence from judgment, surface uncertainty, and drive alignment on decisions and next actions.
  • Represent GDSI on relevant commercialization, indication, and asset forums, prioritizing insights work against decisions with strategic and financial consequence.
  • Own long-term strategic forecasts for GYN and SCLC indications and assigned pipeline assets, incorporating epidemiology, patient segmentation, eligibility, treatment rates, class share, share of class, uptake, duration, compliance, access, price, launch timing, and competitive evolution.
  • Explain forecast level, trajectory, major changes, and key assumptions; reconcile patient, unit, and revenue outputs across indications, geographies, regimens, and time periods.
  • Design base, upside, downside, and event-driven scenarios; quantify direct and second-order effects across indications, products, and shared patient pools, including sequencing, switching, persistence, and cannibalization where applicable.
  • Navigate, audit, modify, extend, and troubleshoot Forecast Horizon and Excel-based models, and build fit-for-purpose models when existing architecture cannot answer the business question.
  • Use waterfalls, variance bridges, sensitivities, tornado analyses, scenario comparisons, and input comparisons to validate key drivers and expose uncertainty.
  • Maintain transparent assumption inventories, source documentation, change logs, model controls, and quality checks so analyses are reproducible and auditable.
  • Define global research and analytics priorities based on decisions, knowledge gaps, and the potential value of additional evidence.
  • Lead qualitative and quantitative primary research with physician, patient, and payer audiences, including treatment-flow work, patient segmentation, drivers and barriers, positioning and message testing, product attribute assessment, demand estimation, and launch-readiness research.
  • Analyze and triangulate secondary sources such as patient-level data, prescription data, epidemiology, treatment patterns, chart audits, and competitive evidence; evaluate population definitions, business rules, sample limitations, and clinical and commercial plausibility.
  • Translate comparative product profiles, clinical outcomes, safety and tolerability, administration, access, evidence maturity, and competitive timing into defensible adoption and share assumptions.
  • Partner with regional and local Insights teams to incorporate market-specific evidence while maintaining globally consistent definitions, assumptions, and forecast logic.
  • Support ongoing phase 3 studies and broader GYN strategy through forecast ownership, market development insights, launch-readiness research, competitive assessment, and evaluation of follow-on opportunities.
  • Support ongoing phase 3 studies and SCLC indication planning through treatment-flow and sequencing analysis, drivers-and-barriers research, launch scenarios, forecast updates, and assessment of evolving competition.
  • Lead opportunity assessments, target-product-profile interpretation, demand estimation, scenario valuation, and evidence planning for selected oncology pipeline assets and external opportunities.
  • Ensure patient-flow logic and treatment-history assumptions are explicit, particularly where prior ADC or class exposure may affect addressability, sequencing, adoption, or duration.
  • Conduct structural, calculation, and reasonableness reviews of key models and analyses; identify double counting, inconsistent populations, hidden constraints, manual overrides, broken links, circularity, and unsupported assumptions.
  • Challenge disconnects among the target product profile, evidence, demand research, competitive TPP assessments, analogs, forecast assumptions, and resulting revenue.
  • Manage external research and analytics partners, ensuring methods fit the purpose, execution remains aligned to decisions, and deliverables withstand technical and business scrutiny.
  • Coach colleagues and contractors on forecast logic, model hygiene, research design, and executive communication; raise team capability without becoming the sole keeper of the analysis.
  • Improve the consistency, efficiency, rigor, and credibility of GDSI processes, templates, and decision support across the oncology portfolio.
  • Create inclusive teams and model inclusion in team management.
  • Develop employees by understanding their skills, experience, aspirations, and potential, and coaching them on current performance and future potential.
  • Connect the team to organizational objectives, align goals and purpose, hold the team accountable, remove barriers, and connect the team to the broader ecosystem.

Desired Qualifications

  • Experience with enterprise forecasting platforms.
  • Experience in gynecologic cancers, lung cancer, antibody-drug conjugates, or oncology pipeline strategy.
  • Forecast Horizon experience.
  • Advanced degree in business, economics, statistics, data science, life sciences, medicine, or another relevant quantitative discipline.
  • Significant pharmaceutical or biotechnology experience, including substantial direct work in forecasting, analytics, and market research.
  • Experience supporting global launches, pipeline assets, indication expansion, and senior governance decisions.
  • Oncology experience across commercial and development-stage questions.
  • Experience leading matrix teams and developing colleagues; direct people-management experience is beneficial but not required unless designated in the final organizational design.

About the Company

Gilead Sciences

Makes medicines for HIV, liver disease and cancer

Gilead Sciences is a biopharmaceutical company that discovers, develops and sells medicines for HIV, viral hepatitis and other liver diseases, cancer and inflammatory conditions. Its HIV business covers both treatment, led by the once-daily pill Biktarvy, and prevention, including Descovy and Yeztugo, a lenacapavir injection given twice a year. In cancer, its Kite unit makes CAR T-cell therapies from patients' own immune cells, and Trodelvy is an antibody-drug conjugate for breast cancer. Gilead earns revenue by selling its drugs to wholesalers, specialty pharmacies, hospitals and governments worldwide after regulatory approval. The company was founded in 1987 and is headquartered in Foster City, California.

Company size
10,001+
Company stage
IPO
Headquarters
Foster City, CA
Founded
1987

Recently Posted Jobs

Explore more opportunities at Gilead Sciences

See more jobs